Vanguard Group Inc Erasca, Inc. Transaction History

Vanguard Group Inc

$4.96 Trillion
Q1 2024

A detailed history of Vanguard Group Inc transactions in Erasca, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 4,338,108 shares of ERAS stock, worth $10.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,338,108

Previous 3,792,343 14.39%

Holding current value

$10.2 Million

Previous $8.08 Million 10.64%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$1.67 - $2.55 $911,427 - $1.39 Million	545,765 Added 14.39%	4,338,108 $8.94 Million
Q4 2023 Feb 14, 2024	SELL	$1.67 - $2.49 $2.21 Million - $3.29 Million	-1,322,769 Reduced 25.86%	3,792,343 $8.08 Million
Q3 2023 Nov 14, 2023	SELL	$1.97 - $2.91 $2.97 Million - $4.39 Million	-1,508,119 Reduced 22.77%	5,115,112 $10.1 Million
Q2 2023 Aug 14, 2023	BUY	$2.57 - $3.3 $1.49 Million - $1.91 Million	579,443 Added 9.59%	6,623,231 $18.3 Million
Q1 2023 May 15, 2023	BUY	$2.74 - $4.44 $597,961 - $968,958	218,234 Added 3.75%	6,043,788 $18.2 Million

Q4 2022 Feb 10, 2023	BUY	$3.89 - $8.57 $873,157 - $1.92 Million	224,462 Added 4.01%	5,825,554 $25.1 Million
Q3 2022 Nov 14, 2022	BUY	$5.82 - $10.68 $3.35 Million - $6.14 Million	575,333 Added 11.45%	5,601,092 $43.7 Million
Q2 2022 Aug 12, 2022	BUY	$4.58 - $8.72 $452,939 - $862,364	98,895 Added 2.01%	5,025,759 $28 Million
Q1 2022 May 13, 2022	BUY	$8.6 - $15.48 $28.4 Million - $51.1 Million	3,299,572 Added 202.76%	4,926,864 $42.4 Million
Q4 2021 Feb 14, 2022	SELL	$12.51 - $22.75 $5 Million - $9.09 Million	-399,479 Reduced 19.71%	1,627,292 $25.4 Million
Q3 2021 Nov 12, 2021	BUY	$17.43 - $24.34 $35.3 Million - $49.3 Million	2,026,771 New	2,026,771 $43 Million

Others Institutions Holding ERAS

# of Institutions

117

Shares Held

74.3M

Call Options Held

7.1K

Put Options Held

40.1K

View Full List

About Erasca, Inc.

Ticker ERAS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 122,147,000
Market Cap $288M
Description
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...

More about ERAS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Erasca, Inc. Transaction History